A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.

@article{Rose2003API,
  title={A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.},
  author={Peter G Rose and John A. Blessing and Harrison G. Ball and James C. Hoffman and David P Warshal and Koen Degeest and David J. Moore},
  journal={Gynecologic oncology},
  year={2003},
  volume={88 2},
  pages={130-5}
}
OBJECTIVES Docetaxel is an inhibitor of microtubule depolymerization and has demonstrated activity in paclitaxel-resistant breast cancer and gynecologic cancer. The Gynecologic Oncology Group (GOG) conducted a study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma to determine its activity, and nature and degree of toxicity, in this cohort of patients. METHODS Patients with platinum- and paclitaxel-resistant ovarian or peritoneal carcinoma, defined as progression while on… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Adoptive immunotherapy against ovarian cancer

Journal of ovarian research • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…